Cohort plc (FRA:C7K)

Germany flag Germany · Delayed Price · Currency is EUR
13.10
+0.40 (3.15%)
At close: Jan 9, 2026
-2.24%
Market Cap590.34M
Revenue (ttm)319.55M
Net Income (ttm)20.79M
Shares Outn/a
EPS (ttm)0.45
PE Ratio28.39
Forward PE17.44
Dividend0.19 (1.53%)
Ex-Dividend DateJan 8, 2026
Volume456
Average Volume240
Open12.40
Previous Close12.70
Day's Range12.40 - 13.10
52-Week Range10.00 - 20.40
Betan/a
RSI61.05
Earnings DateMar 13, 2026

About Cohort

Cohort plc provides various products and services in defense, security, and related markets in the United Kingdom, Germany, Portugal, Australia, North and South America, Asia Pacific, Africa, and other European countries. It operates through Communications and Intelligence; and Sensors and Effectors segments. The company offers chess dynamic, a surveillance and fire control which provides bespoke solutions for land and maritime domains; and and combat systems. It also provides integrated command, control, and communications systems for warships... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services
Founded 2006
Employees 1,619
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol C7K
Full Company Profile

Financial Performance

In 2025, Cohort's revenue was 270.04 million, an increase of 33.33% compared to the previous year's 202.53 million. Earnings were 19.25 million, an increase of 25.68%.

Financial numbers in GBP Financial Statements

News

Cohort PLC (FRA:C7K) (H1 2026) Earnings Call Highlights: Record Revenue Amidst Profitability ...

Cohort PLC (FRA:C7K) (H1 2026) Earnings Call Highlights: Record Revenue Amidst Profitability Challenges

4 weeks ago - GuruFocus

Half Year 2026 Cohort PLC Earnings Presentation Transcript

Half Year 2026 Cohort PLC Earnings Presentation Transcript

4 weeks ago - GuruFocus

Half Year 2026 Cohort PLC Earnings Call Transcript

Half Year 2026 Cohort PLC Earnings Call Transcript

4 weeks ago - GuruFocus

Protara Reports Updated Interim Phase 2 Data Of TARA-002 In Non-muscle Invasive Bladder Cancer

(RTTNews) - Protara Therapeutics, Inc. (TARA) has reported new interim results from Cohort A of its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in BCG- naïve patients with high-grade non-muscle invas...

5 weeks ago - Nasdaq

Protara To Present New Interim Phase 2 Data Of TARA-002 In Bladder Cancer Next Month

(RTTNews) - Protara Therapeutics Inc. (TARA) is scheduled to present new interim data from Cohort A of its ongoing Phase 2 trial assessing investigational cell-based therapy, TARA-002, in patients wit...

7 weeks ago - Nasdaq